

Inhibitors of the Renin–Angiotensin– Aldosterone System and Covid-19 in critically ill elderly patients

Christian Jung (1), Raphael Romano Bruno (1), Bernhard Wernly (2), Michael Joannidis (3), Sandra Oeyen (4), Tilemachos Zafeiridis (5), Brian Marsh (6), Finn H. Andersen (7), Rui Moreno (8), Ana Margarida Fernandes (8) Antonio Artigas (9), Bernardo Bollen Pinto (10), Joerg Schefold (11), Georg Wolff (1), Malte Kelm (1), Dylan W. De Lange (12), Bertrand Guidet (13), Hans Flaatten (14); Jesper Fjølner (15)

on behalf of the COVIP study group

Affiliations

1. Heinrich-Heine-University Duesseldorf, Medical Faculty, Department of Cardiology, Pulmonology and Vascular Medicine, Düsseldorf, Germany
2. Department of Cardiology, Paracelsus Medical University, Salzburg, Austria
3. Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria
4. Department of Intensive Care 1K12IC Ghent University Hospital, Ghent, Belgium
5. Intensive Care Unit General Hospital of Larissa, Larissa, Greece
6. Mater Misericordiae University Hospital, Dublin, Ireland
7. Dep. Of Anaesthesia and Intensive Care, Ålesund Hospital, Ålesund, Norway. Dep. of Circulation and medical imaging, Norwegian university of Science and Technology, Trondheim, Norway
8. Unidade de Cuidados Intensivos Neurocríticos e Trauma. Hospital de São José, Centro Hospitalar Universitário de Lisboa Central, Faculdade de Ciências Médicas de Lisboa, Nova Médical School, Lisbon, Portugal
9. Department of Intensive Care Medecine, CIBER Enfermedades Respiratorias, Corporacion Sanitaria Universitaria Parc Tauli, Autonomous University of Barcelona, Sabadell, Spain

10. Department of Acute Medicine, Geneva University Hospitals, Geneva, Switzerland
11. Department of Intensive Care Medicine, Inselspital, Universitätsspital, University of Bern, Bern, Switzerland
12. Department of Intensive Care Medicine, University Medical Center, University Utrecht, the Netherlands
13. Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, F-75012, France
14. Department of Clinical Medicine, University of Bergen, Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway
15. Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark

Corresponding author:

Christian Jung, M.D. PhD

Division of Cardiology, Pulmonology, and Vascular Medicine

University Duesseldorf

Moorenstraße 5, 40225 Duesseldorf

Germany

Email: christian.jung@med.uni-duesseldorf.de

Word count: 609 (main text)

Conflict of Interests

The authors declare that they have no competing interests.

Financial Disclosure statement

No (industry) sponsorship has been received for this investigator-initiated study.

Acknowledgments

The support of the study in France by Assistance Publique-Hôpitaux de Paris is greatly appreciated.

Trial registration number

NCT04321265

SARS-CoV-2, the coronavirus that causes COVID-19, uses the membrane-bound form of the aminopeptidase angiotensin-converting enzyme 2 (ACE2) to enter cells. Since ACE2 is centrally involved in the regulation of the renin-angiotensin-aldosterone system (RAAS), it has been speculated that RAAS inhibitors influence clinical courses. Mehta et al. found no association between use of RAAS inhibitors and likelihood of COVID-19 testing positivity in 18,472 patients. (1) Reynolds et al. performed a study based on data from electronic health records (5,894 COVID-19 cases), where a Bayesian analysis showed no positive association of RAAS inhibitors with either a positive test result or severe illness. Mancina et al. also found no evidence in a population-based case-control study (6,272 case-patients) for RAAS inhibitors to affect the risk of contracting COVID-19. (2)

However, although these retrospective studies report essential data, they are of limited use to inform on elderly, co-morbid and severely ill patients, who represent the most vulnerable group of patients affected by Covid-19 and are also most likely treated with RAAS inhibitors within the general population. To investigate special clinical features in COVID-19, the COVIP study (Very old intensive care patients, VIP-network; NCT04321265) is ongoing. COVIP prospectively includes patients equal to or above 70 years of age with proven COVID-19 who are admitted to an intensive care unit (ICU). A total of 244 ICUs in 38 countries are registered to participate in COVIP. The primary endpoint is death after 30 days. Inclusion criteria are 1) Age \geq 70 years 2) ICU-Admission 3) Infection with SARS-CoV-2. Furthermore, a follow-up will be performed after 3 months to assess death and quality of life. The prospective design aims to create high-quality data about risk factors, comorbidities, pre-existing frailty, ICU-treatment including treatment limitations, and the use of experimental drugs in this critically ill patient collective of elderly patients. **An interim analysis was performed on 7th of May with respect to RAAS inhibitor use.**

In total, 324 patients were evaluated (Table 1): 157 (48%) were on RAAS inhibitors, 62 (19%) on angiotensin-converting-enzyme (ACE) inhibitors (ACE-I) and 95 (29%) on angiotensin II receptor blockers (ARB) before disease onset. Overall ICU-mortality was 45% and was similar between patients with and without previous ARB (45% vs. 45%; $p=0.98$), but lower in patients with previous ACE-I (31% vs. 49%; $p=0.01$). A propensity for being on ACE-I was calculated using logistic regression, the covariates were age, body mass index, sex, sequential Organ Failure Assessment (SOFA) score, as well as existing comorbidities of chronic heart failure, ischemic heart disease, renal insufficiency, chronic pulmonary disease, arterial hypertension and diabetes mellitus (Table 1). The primary endpoint was ICU mortality. Both univariable (model 1) and multivariable (model 2, propensity score correction) logistic regression models were built to evaluate associations with the primary endpoint. Odds ratios (OR, model 1, Table 1) and adjusted odds ratios (aOR, model 2) with respective 95% confidence intervals (CI) were calculated. The univariate association of previous ACE-I with lower mortality (OR 0.46, 95% CI 0.26-0.84; $p=0.01$; Table 1) remained statistically significant after propensity score adjustment (aOR 0.32, 95% CI 0.15-0.67; $p=0.002$).

In conclusion, in a prospective study of elderly, critically ill and co-morbid patients, we do find a beneficial association of previous ACE-I use with ICU survival. The current data confirms the notion that there is either a positive or no effect of RAAS inhibitor use. In addition, our data support the current view that continuation of RAAS inhibitor use should be recommended. (3) In summary, this is the first prospective multinational study that demonstrates beneficial associations of ACE-I in high risk Covid-19 patients and thus impact on daily practice. However, further research evaluating potential causality is warranted.

References

1. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology* 2020.
2. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med* 2020.
3. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic. *Hypertension* 2020; 75(6):1382-1385.

Table legends

Table 1, title: Patient characteristics

Table 1, legend: Patient characteristics in all patients and in survivors and non-survivors, respectively. All continuous variables were non-normally distributed, are presented as median (range) and were compared using Mann-Whitney-U tests; categorical variables are presented as n (%) and were compared using Chi² tests; p-values and Cochran-Mantel-Haenszel estimates are reported, presented as odds ratios (OR) with 95% confidence intervals (CI); statistical significance was assumed at $p < 0.05$ and is indicated by *.

Table 1 – Patient characteristics

	All patients (n = 324)	Survivors (n = 177)	Non-Survivors (n = 147)	p-values	OR (95% CI)
Age	75 (70-93)	74 (70-93)	77 (70-88)	<0.0001 *	-
BMI	26.8 (18.3-51.4)	26.9 (18.3-41.5)	26.5 (18.3-51.4)	0.65	-
Male/female sex	224/100 (69/31)	116/61 (52/61)	108/39 (48/39)	0.12	1.46 (0.90-2.35)
SOFA score	6 (1-17)	5 (2-13)	7 (1-17)	<0.0001 *	-
Chronic heart failure	45 (14.1)	20 (11.5)	25 (17.2)	0.14	1.60 (0.85-3.03)
Ischemic heart disease	63 (19.7)	31 (17.8)	32 (22.1)	0.40	1.31 (0.75-2.27)
Renal insufficiency	49 (15.2)	18 (10.2)	31 (21.1)	0.007 *	2.35 (1.25-4.40) *
Pulmonary disease	82 (25.5)	41 (23.3)	41 (28.3)	0.31	1.30 (0.79-2.15)
Arterial hypertension	211 (65.1)	115 (65.0)	96 (65.3)	0.95	1.02 (0.64-1.61)
Diabetes mellitus	95 (29.4)	48 (27.1)	47 (32.2)	0.32	1.28 (0.79-2.06)
ACE-I	62 (19.1)	43 (24.3)	19 (12.9)	0.01 *	0.46 (0.26-0.84) *
ARB	95 (29.3)	52 (29.4)	43 (29.3)	0.98	0.99 (0.62-1.61)

Table 1: Patient characteristics in all patients and in survivors and non-survivors, respectively. All continuous variables were non-normally distributed, are presented as median (range) and were compared using Mann-Whitney-U tests; categorical variables are presented as n (%) and were compared using Chi² tests; p-values and Cochran-Mantel-Haenszel estimates are reported, presented as odds ratios (OR) with 95% confidence intervals (CI); statistical significance was assumed at $p < 0.05$ and is indicated by *.